Feed / PSNL

Personalis, Inc.

PSNL

Healthcare · 16.24 -0.8% today

Isolated · not yet confirmedMarket checked 1 Oct, 15:45 GMT-4

Market read

No connected market move is active around Personalis, Inc..

No new filing conclusion is available. 0 of 0 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 28 directly disclosed connections are confirming.

Company-0.8% todayVolume comparison unavailable
Market groupNo active group readNo durable group available
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
  • PSNL's market-adjusted activity becomes unusual and at least one connected name confirms.

Invalidation: The isolated read changes if PSNL's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Diagnostics & Research

No new filing conclusion is available. 0 of 0 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 28 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • PSNL's market-adjusted activity becomes unusual and at least one connected name confirms.

Company research

Understand the business, not just the ticker

As of Oct 1, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods9
Price observations333
Usable filing statements115
Verified relationships12
Evidence supporting the case

No qualifying supportive evidence was identified.

Evidence challenging the case
  • Latest annual revenue changed -17.7% year over year.
  • Operating margin changed -45.8 percentage points in the latest annual period.
  • Net margin changed -20.6 percentage points in the latest annual period.
  • Capital investment and capacity has repeated adverse evidence across 4 filings.
  • Product pipeline and R&D has repeated adverse evidence across 4 filings.
Questions before a position

No credible peer-relative valuation comparison is available yet.

Longer-term price context

Price as of Sep 30, 2026

16.29
6m+126.6%12m+184.3%24m—
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2021-12-31$85.5M+8.7%$-1.49+27.7%
2022-12-31$65.0M-23.9%$-2.48+4.1%
2023-12-31$73.5M+13.0%$-2.25+5.4%
2024-12-31$84.6M+15.2%$-1.37+23.0%
2025-12-31$69.6M-17.7%$-0.91—

What management says matters

Persistent and emerging business drivers

Capital investment and capacitynegative · 4 filings
“The increase in cash used by investing activities was due to a $2.7 million increase in investment of our cash into short-term investments, $20.2 million lower proceeds from the maturity of short-term investments, and a $0.6 million increase in capital expend…”
10-Q · May 7, 2026 ↗
Product pipeline and R&Dnegative · 4 filings
“Research and development The increase in research and development expenses in the first quarter of 2026 was primarily due to an increase in personnel and personnel-related costs, expenses related to IT support, and lab supplies utilized.”
10-Q · May 7, 2026 ↗
Credit and interest ratesmixed · 3 filings
“Interest Income, Interest Expense, and Other Income (Expense), Net The following table shows interest income and expense, and other income (expense), net (in thousands, except percentages): 30 Table of Contents Three Months Ended March 31, 2026 2025 Change In…”
10-Q · May 7, 2026 ↗
Demand and volumenegative · 2 filings
“For example, the revenue we recognized during the contract year that began in September 2020 significantly exceeded the value of the VA MVP contracted order we received in September 2020 because we continued to receive after such date, and subsequently proces…”
10-K · Feb 26, 2026 ↗

Valuation discipline

Peer-relative valuation withheld

Jodie found no industry-matched filing peers suitable for a valuation comparison. It will not substitute broader financial-sector names.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

16.24-0.8% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 1 Oct, 15:45 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for PSNL. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for PSNL. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind PSNL

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

MRNA25.0% of PSNLcustomerMay 7, 2026 ▾

“For example, we are providing genomic testing services to ModernaTX, Inc.”

NTRANatera, Inc.customerMay 7, 2026 ▾

“First Quarter 2026 Highlights Total revenue of $15.5 million decreased 25%, or $5.1 million, during the first quarter of 2026 compared to the first quarter of 2025, due to (i) lower revenue from pharma testing services and other customers; (ii) an expected re…”

Depended on by

CAICaris Life Sciences, Inc.competitorMar 3, 2026 ▾

“Our competitors in blood-based molecular profiling for MRD tracking and treatment monitoring include Natera, Guardant Health, SAGA Diagnostics, Personalis, BillionToOne, Quest Diagnostics and Adaptive Biotechnologies.”

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 29 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

PSNL is currently a Follower in the organic co-movement group Unknown Theme. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for PSNL; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.